PL1730191T3 - Immunoglobuliny wiążące hosm - Google Patents

Immunoglobuliny wiążące hosm

Info

Publication number: PL1730191T3
Authority: PL; Poland
Prior art keywords: hosm; immunoglobulin binding; immunoglobulin; binding; binding hosm
Prior art date: 2004-03-30

Application number

PL05733043T

Other languages

English (en)

Inventor

Jonathan Henry Ellis

Alexandre Eon-Duval

Volker Germaschewski

Christopher Plumpton

Nicholas Timothy Rapson

Michael Robert West

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-30

Filing date

2005-03-29

Publication date

2011-12-30

2004-03-30 Priority claimed from GB0407197A external-priority patent/GB0407197D0/en

2004-03-30 Priority claimed from GB0407193A external-priority patent/GB0407193D0/en

2005-03-29 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2011-12-30 Publication of PL1730191T3 publication Critical patent/PL1730191T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Microbiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PL05733043T 2004-03-30 2005-03-29 Immunoglobuliny wiążące hosm PL1730191T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0407197A GB0407197D0 (en)	2004-03-30	2004-03-30	Immunoglobulins
GB0407193A GB0407193D0 (en)	2004-03-30	2004-03-30	Immunoglobulins
EP05733043A EP1730191B1 (en)	2004-03-30	2005-03-29	Immunoglobulin binding hosm
PCT/GB2005/001147 WO2005095457A2 (en)	2004-03-30	2005-03-29	Immunoglobulins

Publications (1)

Publication Number	Publication Date
PL1730191T3 true PL1730191T3 (pl)	2011-12-30

Family

ID=35064447

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05733043T PL1730191T3 (pl)	2004-03-30	2005-03-29	Immunoglobuliny wiążące hosm

Country Status (24)

Country	Link
US (2)	US7858753B2 (pl)
EP (2)	EP2404935A1 (pl)
JP (1)	JP4809828B2 (pl)
KR (1)	KR100942849B1 (pl)
AR (1)	AR048516A1 (pl)
AT (1)	ATE515515T1 (pl)
AU (1)	AU2005229457B2 (pl)
BR (1)	BRPI0509367A (pl)
CA (1)	CA2562953A1 (pl)
CY (1)	CY1112192T1 (pl)
DK (1)	DK1730191T3 (pl)
HR (1)	HRP20110657T1 (pl)
IL (1)	IL178119A0 (pl)
MA (1)	MA28541B1 (pl)
NO (1)	NO20064886L (pl)
NZ (1)	NZ550225A (pl)
PE (1)	PE20060287A1 (pl)
PL (1)	PL1730191T3 (pl)
PT (1)	PT1730191E (pl)
RU (5)	RU2429245C2 (pl)
SG (1)	SG151292A1 (pl)
SI (1)	SI1730191T1 (pl)
TW (1)	TWI365746B (pl)
WO (1)	WO2005095457A2 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20080090408A (ko)	2005-11-30	2008-10-08	아보트 러보러터리즈	항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
SG10201706600VA (en)	2005-11-30	2017-09-28	Abbvie Inc	Monoclonal antibodies and uses thereof
WO2007098547A1 (en) *	2006-03-01	2007-09-07	Apollo Life Sciences Limited	A molecule and chimeric molecules thereof
TWI422387B (zh)	2006-05-25	2014-01-11	Glaxo Group Ltd	免疫球蛋白
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
MX2011000117A (es)	2008-07-10	2011-02-25	Toray Industries	Composicion farmaceutica para tratamiento y prevencion de cancer.
AU2009278386B2 (en)	2008-08-05	2015-05-21	Toray Industries, Inc.	Pharmaceutical composition for treatment and prevention of cancers
CA2735193A1 (en) *	2008-08-26	2010-03-11	Macrogenics, Inc.	T-cell receptor antibodies and methods of use thereof
US8309688B2 (en) *	2008-12-30	2012-11-13	Centocor Ortho Biotech Inc.	Monkey homolog of human oncostatin M and methods of use thereof
EP2258723A1 (en) *	2009-06-02	2010-12-08	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Treatment of oncostatin M receptor ß mediated heart failure
CA2788718C (en)	2010-02-04	2019-05-21	Shinichi Kobayashi	Caprin-1 antibody for treating and/or preventing cancer
RU2598258C2 (ru)	2010-02-04	2016-09-20	Торэй Индастриз, Инк.	Фармацевтическая композиция для лечения и/или профилактики рака
RU2567657C2 (ru)	2010-02-04	2015-11-10	Торэй Индастриз, Инк.	Фармацевтическая композиция для лечения и/или профилактики рака
MX340014B (es)	2010-02-04	2016-06-22	Toray Industries	Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2011096533A1 (ja)	2010-02-04	2011-08-11	東レ株式会社	癌の治療及び／又は予防用医薬組成物
EP2558494B1 (en)	2010-04-15	2018-05-23	AbbVie Inc.	Amyloid-beta binding proteins
US9062101B2 (en)	2010-08-14	2015-06-23	AbbVie Deutschland GmbH & Co. KG	Amyloid-beta binding proteins
WO2012051111A2 (en)	2010-10-13	2012-04-19	Janssen Biotech, Inc.	Human oncostatin m antibodies and methods of use
SI2643352T1 (sl) *	2010-11-23	2018-12-31	Glaxo Group Limited	Antigen-vezavni proteini na onkostatin M (OSM)
CN103764825B (zh)	2011-08-04	2015-09-02	东丽株式会社	癌的治疗和/或预防用药物组合物
CN103717739B (zh)	2011-08-04	2015-07-29	东丽株式会社	癌的治疗和/或预防用药物组合物
EP2740798B1 (en)	2011-08-04	2016-12-07	Toray Industries, Inc.	Cancer treatment and/or prevention drug composition
WO2013125654A1 (ja)	2012-02-21	2013-08-29	東レ株式会社	癌の治療及び／又は予防用医薬組成物
AU2013223147B2 (en)	2012-02-21	2017-10-05	Toray Industries, Inc.	Pharmaceutical composition for treatment and/or prevention of cancer
MX360208B (es)	2012-02-21	2018-10-24	Toray Industries	Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PT2818481T (pt)	2012-02-21	2019-10-25	Toray Industries	Composição farmacêutica para tratamento e/ou prevenção de cancro
EP2832365B1 (en)	2012-03-30	2017-11-01	Toray Industries, Inc.	Pharmaceutical composition for treatment and/or prevention of liver cancer
JP6107655B2 (ja)	2012-03-30	2017-04-05	東レ株式会社	胆嚢癌の治療及び／又は予防用医薬組成物
KR101882366B1 (ko)	2013-05-30	2018-07-30	키닉사 파마슈티컬스, 리미티드	온코스타틴 m 수용체 항원 결합 단백질
PT3031826T (pt)	2013-08-09	2019-01-18	Toray Industries	Composição farmacêutica para o tratamento e/ou a prevenção do cancro
US9550828B2 (en)	2013-09-05	2017-01-24	Boise State University	Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
ES2923641T3 (es)	2013-12-30	2022-09-29	Epimab Biotherapeutics Inc	Inmunoglobulina con Fabs en tándem y usos de la misma
LT3110434T (lt) *	2014-02-24	2018-12-27	Takeda Gmbh	Sulieti uti baltymai
WO2016046738A1 (en) *	2014-09-24	2016-03-31	Università Degli Studi Di Padova	Composition to induce bone marrow stem cell mobilization
JP6787904B2 (ja) *	2015-01-29	2020-11-18	アレストレーディングソシエテアノニム	高度に正に荷電したタンパク質のイムノアッセイ
AU2017214692B2 (en)	2016-02-06	2021-11-04	Epimab Biotherapeutics, Inc.	Fabs-in-tandem immunoglobulin and uses thereof
US20190112370A1 (en)	2016-03-28	2019-04-18	Toray Industries, Inc.	Pharmaceutical composition for treatment and/or prevention of cancers
GB201614627D0 (en) *	2016-08-30	2016-10-12	Glaxosmithkline Ip Dev Ltd	Antigen binding proteins
JP7368453B2 (ja)	2018-05-03	2023-10-24	シャンハイエピムアブバイオセラピューティクスカンパニーリミテッド	Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
FR3090637A1 (fr) *	2018-12-21	2020-06-26	Universite De Poitiers	Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en)	2019-04-11	2023-04-25	Boise State University	Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use
MX2023004500A (es)	2020-10-19	2023-05-10	Zoetis Services Llc	Anticuerpos contra el receptor beta de la oncostatina m canina y felina y usos de estos.

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DD266710A3 (de)	1983-06-06	1989-04-12	Ve Forschungszentrum Biotechnologie	Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en)	1984-10-30	1989-11-07	Phillips Petroleum Company	Transformation of yeasts of the genus pichia
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
GB8610600D0 (en)	1986-04-30	1986-06-04	Novo Industri As	Transformation of trichoderma
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
WO1990005144A1 (en)	1988-11-11	1990-05-17	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
FR2646437B1 (fr)	1989-04-28	1991-08-30	Transgene Sa	Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en)	1989-05-16	2001-09-18	Scripps Research Institute	Method for tapping the immunological repertoire
EP0402226A1 (en)	1989-06-06	1990-12-12	Institut National De La Recherche Agronomique	Transformation vectors for yeast yarrowia
BR9206313A (pt)	1991-07-25	1995-04-11	Idec Pharma Corp	Anticorpos recombinantes para terapia humana.
JP3540315B2 (ja)	1991-09-23	2004-07-07	メディカルリサーチカウンシル	キメラ抗体の製造−組合せアプローチ
GB9122820D0 (en)	1991-10-28	1991-12-11	Wellcome Found	Stabilised antibodies
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en)	1992-02-19	1992-04-08	Scotgen Ltd	Antibodies with germ-line variable regions
ATE149570T1 (de)	1992-08-17	1997-03-15	Genentech Inc	Bispezifische immunoadhesine
AU6852594A (en)	1993-06-03	1995-01-03	Therapeutic Antibodies Inc.	Production of antibody fragments
JP3622208B2 (ja)	1993-06-11	2005-02-23	東ソー株式会社	骨粗鬆症治療方法及び治療薬
US5429746A (en)	1994-02-22	1995-07-04	Smith Kline Beecham Corporation	Antibody purification
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
GB9806530D0 (en) *	1998-03-26	1998-05-27	Glaxo Group Ltd	Inflammatory mediator
WO1999055369A1 (en)	1998-04-28	1999-11-04	Smithkline Beecham Corporation	Monoclonal antibodies with reduced immunogenicity
WO2004006955A1 (en)	2001-07-12	2004-01-22	Jefferson Foote	Super humanized antibodies
GB0216648D0 (en)	2002-07-18	2002-08-28	Lonza Biologics Plc	Method of expressing recombinant protein in CHO cells

2005
- 2005-03-29 WO PCT/GB2005/001147 patent/WO2005095457A2/en not_active Ceased
- 2005-03-29 HR HR20110657T patent/HRP20110657T1/hr unknown
- 2005-03-29 JP JP2007505621A patent/JP4809828B2/ja not_active Expired - Fee Related
- 2005-03-29 CA CA002562953A patent/CA2562953A1/en not_active Abandoned
- 2005-03-29 NZ NZ550225A patent/NZ550225A/en not_active IP Right Cessation
- 2005-03-29 EP EP11167424A patent/EP2404935A1/en not_active Withdrawn
- 2005-03-29 AU AU2005229457A patent/AU2005229457B2/en not_active Ceased
- 2005-03-29 US US10/594,293 patent/US7858753B2/en not_active Expired - Fee Related
- 2005-03-29 PL PL05733043T patent/PL1730191T3/pl unknown
- 2005-03-29 PE PE2005000360A patent/PE20060287A1/es not_active Application Discontinuation
- 2005-03-29 RU RU2006134477/10A patent/RU2429245C2/ru not_active IP Right Cessation
- 2005-03-29 AT AT05733043T patent/ATE515515T1/de active
- 2005-03-29 EP EP05733043A patent/EP1730191B1/en not_active Expired - Lifetime
- 2005-03-29 BR BRPI0509367-8A patent/BRPI0509367A/pt not_active IP Right Cessation
- 2005-03-29 SI SI200531371T patent/SI1730191T1/sl unknown
- 2005-03-29 PT PT05733043T patent/PT1730191E/pt unknown
- 2005-03-29 SG SG200901959-7A patent/SG151292A1/en unknown
- 2005-03-29 DK DK05733043.3T patent/DK1730191T3/da active
- 2005-03-29 KR KR1020067022671A patent/KR100942849B1/ko not_active Expired - Fee Related
- 2005-03-30 TW TW094110049A patent/TWI365746B/zh not_active IP Right Cessation
- 2005-03-30 AR ARP050101233A patent/AR048516A1/es unknown
2006
- 2006-09-14 IL IL178119A patent/IL178119A0/en unknown
- 2006-10-18 MA MA29397A patent/MA28541B1/fr unknown
- 2006-10-26 NO NO20064886A patent/NO20064886L/no not_active Application Discontinuation
2009
- 2009-03-10 RU RU2009108147/10A patent/RU2009108147A/ru not_active Application Discontinuation
- 2009-03-10 RU RU2009108148/10A patent/RU2009108148A/ru not_active Application Discontinuation
- 2009-03-10 RU RU2009108149/10A patent/RU2009108149A/ru not_active Application Discontinuation
2010
- 2010-11-16 US US12/947,371 patent/US20110245470A1/en not_active Abandoned
2011
- 2011-05-30 RU RU2011121419/10A patent/RU2011121419A/ru not_active Application Discontinuation
- 2011-09-29 CY CY20111100943T patent/CY1112192T1/el unknown

Also Published As

Publication number	Publication date
KR20060135049A (ko)	2006-12-28
BRPI0509367A (pt)	2007-09-11
JP4809828B2 (ja)	2011-11-09
RU2009108148A (ru)	2010-09-20
EP1730191B1 (en)	2011-07-06
RU2011121419A (ru)	2012-12-10
JP2007530068A (ja)	2007-11-01
HK1103747A1 (en)	2007-12-28
KR100942849B1 (ko)	2010-02-17
AU2005229457A1 (en)	2005-10-13
US20110245470A1 (en)	2011-10-06
IL178119A0 (en)	2006-12-31
MA28541B1 (fr)	2007-04-03
US7858753B2 (en)	2010-12-28
CY1112192T1 (el)	2015-12-09
RU2006134477A (ru)	2008-05-10
ATE515515T1 (de)	2011-07-15
PE20060287A1 (es)	2006-05-16
EP2404935A1 (en)	2012-01-11
TWI365746B (en)	2012-06-11
NO20064886L (no)	2006-12-12
WO2005095457A2 (en)	2005-10-13
TW200602079A (en)	2006-01-16
RU2429245C2 (ru)	2011-09-20
EP1730191A2 (en)	2006-12-13
SG151292A1 (en)	2009-04-30
PT1730191E (pt)	2011-10-04
WO2005095457A3 (en)	2006-04-27
HRP20110657T1 (hr)	2011-10-31
AR048516A1 (es)	2006-05-03
US20070286861A1 (en)	2007-12-13
AU2005229457B2 (en)	2010-11-25
SI1730191T1 (sl)	2011-11-30
CA2562953A1 (en)	2005-10-13
RU2009108149A (ru)	2010-09-20
RU2009108147A (ru)	2010-09-20
DK1730191T3 (da)	2011-10-17
NZ550225A (en)	2010-11-26

Publication	Publication Date	Title
SI1730191T1 (sl)	2011-11-30	Imunoglobulin-vezavni hOSM
TWI307630B (en)	2009-03-21	Immunoglobulins
IL179661A0 (en)	2007-05-15	Il-13 binding agents
IL181575A0 (en)	2007-07-04	Anti-ox40l antibodies
ZA201301416B (en)	2014-12-23	Binding molecules
IL182279A0 (en)	2007-07-24	Angiopoietin-2-specific binding agents
IL228033A0 (en)	2013-09-30	Antibodies
GB0404187D0 (en)	2004-03-31	Binding agents
GB0521991D0 (en)	2005-12-07	Siglec-9 binding agents
GB0420466D0 (en)	2004-10-20	Anti-glucan antibodies
ZA200701952B (en)	2008-10-29	Anti-OX40L antibodies
IL184137A (en)	2010-11-30	Binding implement for document
EP1710096A4 (en)	2015-08-05	BINDING DEVICE
IL181492A0 (en)	2007-07-04	Binding member towards pneumolysin
GB0410627D0 (en)	2004-06-16	Specific binding members
ZA200702249B (en)	2008-06-25	Binding member towards pneumolysin
GB0520523D0 (en)	2005-11-16	Object binding
EP1780221A4 (en)	2007-10-03	ANTI-SYNOVIOLIN ANTIBODY
ZA200610612B (en)	2009-09-30	Immunoglobulins
GB0407197D0 (en)	2004-05-05	Immunoglobulins
GB0418415D0 (en)	2004-09-22	Antibody
GB0420771D0 (en)	2004-10-20	Antibody
GB0407193D0 (en)	2004-05-05	Immunoglobulins
GB0423675D0 (en)	2004-11-24	Immunoglobulins
PL366676A1 (pl)	2005-10-03	Wkładka łącząca